Company news
Hansoh Pharmaceutical Group Company Limited (HKEX:3692) news
Hansoh Pharmaceutical Group Company Limited news releases on 6ix. Latest, Oct 2, 2026: Monthly Return of Equity Issuer on Movements in Securities…
Press releases & updates
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATUS OF AUMOLERTINIB IN THE EU
September 27, 2026
Hansoh Pharmaceutical : PHARMA ANNOUNCES PIVOTAL PHASE 3 CLINICAL TRIAL OF HS-10374 IN THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS MET THE CO-PRIMARY ENDPOINTS
September 20, 2026
Hansoh Pharmaceutical : WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC
September 14, 2026
Hansoh Pharmaceutical : 2026 WCLC | HANSOH PHARMA ANNOUNCES INTERIM RESULTS FROM PHASE 3 ARTEMIS-008 STUDY OF RISVUTATUG REZETECAN (HS-20093) IN PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
September 12, 2026
Hansoh Pharmaceutical : BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETCAN (HS-20093) FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA
September 7, 2026
Hansoh Pharmaceutical : PHARMA ANNOUNCES ARTEMIS-011 PHASE 3 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET PRIMARY ENDPOINT OF IRC-ASSESSED PFS IN OSTEOSARCOMA
July 28, 2026
Hansoh Pharmaceutical : A MARK OF EXCELLENCE!HANSOHPHARMACEUTICAL SECURES A TOP THREE SPOT AMONG "MODEL INDUSTRIAL ENTERPRISES FOR CHINA’S PHARMACEUTICAL R&D PIPELINES" FOR THE TENTH CONSECUTIVE YEAR.
July 15, 2026
Hansoh Pharmaceutical : PHARMA ANNOUNCES LICENSE COLLABORATION AND STRATEGIC INVESTMENT WITH AVERE FOR ORAL IL‑23 ASSET HS‑20118
July 14, 2026
Hansoh Pharmaceutical : PHARMA ANNOUNCES ARTEMIS-008 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
July 10, 2026
Hansoh Pharmaceutical : ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTS PHASE 2 DATA OF RISVUTATUG REZETECAN (RIS-REZ) IN RELAPSED OR REFRACTORY SARCOMAS
June 18, 2026
Hansoh Pharmaceutical : ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC
June 18, 2026
Hansoh Pharmaceutical : PIVOTAL TRIAL OF AMEILE® PLUS CHEMOTHERAPY (AENEAS2) PUBLISHED IN THE LANCET ONCOLOGY
June 17, 2026
EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML)
June 12, 2026
Hansoh Pharmaceutical : SID 2026 | HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS
May 15, 2026
Hansoh Pharmaceutical : AACR 2026 | HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC
April 22, 2026
Hansoh Pharmaceutical : AACR 2026 | HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS
April 19, 2026
Hansoh Pharmaceutical : AAN 2026 | HANSOH PHARMA PRESENTED PHASE 1B/2 DATA OF HS-10506 (A SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST) IN INSOMNIA
April 17, 2026
Hansoh Pharmaceutical : PHARMA – XINYUE’S THIRD INDICATION APPROVED FOR MARKETING FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS
April 3, 2026
Hansoh Pharmaceutical : WCN 2026 | HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-10542（A COMPLEMENT FACTOR B INHIBITOR）IN HEALTHY PARTICIPANTS
March 27, 2026
Hansoh Pharmaceutical : ELCC 2026 | HANSOH PHARMA PRESENTED RESULTS OF DALMELITINIB (HS-10241, A HIGHLY SELECTIVE MET-TKI) COMBINED WITH AUMOLERTINIB FROM A PHASE IB STUDY IN PATIENTS WITH MET-AMPLIFIED ADVANCED NSCLC POST EGFR TKI
March 26, 2026
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
March 9, 2026
Hansoh Pharmaceutical : OLATOREPATIDE (HS-20094) ACHIEVES UP TO 19.3% WEIGHT LOSS AT WEEK 48 IN PHASE 3 STUDY WITH FAVORABLE GASTROINTESTINAL TOLERABILITY
March 6, 2026
Hansoh Pharmaceutical : CANCER CELL PUBLISHES PHASE 1 LUNG CANCER RESULTS OF RISVUTATUG REZETECAN
March 5, 2026
Hansoh Pharmaceutical : ASCO GU 2026 | HANSOH PHARMA PRESENTED PHASE 2 DATA OF RISVUTATUG REZETECAN IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
February 27, 2026
Hansoh Pharmaceutical : ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA
February 27, 2026
Hansoh Pharmaceutical : PHARMA ANNOUNCES THE NEW DRUG APPLICATION OF DALMELITINIB MESYLATE TABLETS WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
February 26, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
February 3, 2026
Hansoh Pharmaceutical : CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC
October 23, 2025
Hansoh Pharmaceutical : GRANTS ROCHE AN EXCLUSIVE LICENSE TO NOVEL CDH17-TARGETING ADC HS-20110
October 16, 2025